Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules

被引:119
作者
Zeng, G [1 ]
Touloukian, CE [1 ]
Wang, X [1 ]
Restifo, NP [1 ]
Rosenberg, SA [1 ]
Wang, RF [1 ]
机构
[1] NIH, Surg Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.4049/jimmunol.165.2.1153
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In previous studies, the shared cancer-testis Ag, NY-ESO-1, was demonstrated to be recognized by both Abs and CD8(+) T cells. Gene expression of NY-ESO-1 was detected in many tumor types, Including melanoma, breast, and lung cancers, but was not found in normal tissues, with the exception of testis, In this study, we describe the identification of MHC class II-restricted T cell epitopes from NY-ESO-1, Candidate CD4(+) T cell peptides were first identified using HLA-DR4 transgenic mice immunized with the NY-ESO-1 protein. NY-ESO-l-specific CD4(+) T cells were then generated from PBMC of a patient with melanoma stimulated with the candidate peptides in vitro. These CD4(+) T cells recognized NY-ESO-1 peptides or protein pulsed on HLA-DR4(+) EBV B cells, and also recognized tumor cells expressing HLA-DR4 and NY-ESO-I, A 10-mer peptide (VLLKEFTVSG) was recognized by CD4(+) T cells. These studies provide new opportunities for developing more effective vaccine strategies by using tumor-specific CD4(+) T cells. This approach may be applicable to the identification of CD4(+) T cell epitopes from many known tumor Ags recognized by CD8(+) T cells.
引用
收藏
页码:1153 / 1159
页数:7
相关论文
共 40 条
[1]   Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma [J].
Bloom, MB ;
PerryLalley, D ;
Robbins, PF ;
Li, Y ;
ElGamil, M ;
Rosenberg, SA ;
Yang, JC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) :453-459
[2]   Coupling and uncoupling of tumor immunity and autoimmunity [J].
Bowne, WB ;
Srinivasan, R ;
Wolchok, JD ;
Hawkins, WG ;
Blachere, NE ;
Dyall, R ;
Lewis, JJ ;
Houghton, AN .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (11) :1717-1722
[3]   Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes [J].
Chaux, P ;
Vantomme, V ;
Stroobant, V ;
Thielemans, K ;
Corthals, J ;
Luiten, R ;
Eggermont, AMM ;
Boon, T ;
van der Bruggen, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (05) :767-777
[4]   A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening [J].
Chen, YT ;
Scanlan, MJ ;
Sahin, U ;
Tureci, O ;
Gure, AO ;
Tsang, SL ;
Williamson, B ;
Stockert, E ;
Pfreundschuh, M ;
Old, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :1914-1918
[5]  
HAAS GG, 1988, AM J REPROD IMMUNOL, V18, P47
[6]   IMPLICATING A ROLE FOR IMMUNE RECOGNITION OF SELF IN TUMOR REJECTION - PASSIVE-IMMUNIZATION AGAINST THE BROWN LOCUS PROTEIN [J].
HARA, I ;
TAKECHI, Y ;
HOUGHTON, AN .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05) :1609-1614
[7]   CANCER ANTIGENS - IMMUNE RECOGNITION OF SELF AND ALTERED SELF [J].
HOUGHTON, AN .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :1-4
[8]   The central role of CD4+ T cells in the antitumor immune response [J].
Hung, K ;
Hayashi, R ;
Lafond-Walker, A ;
Lowenstein, C ;
Pardoll, D ;
Levitsky, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (12) :2357-2368
[9]   HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis [J].
Ito, K ;
Bian, HJ ;
Molina, M ;
Han, JH ;
Magram, J ;
Saar, E ;
Belunis, C ;
Bolin, DR ;
Arceo, R ;
Campbell, R ;
Falcioni, F ;
Vidovic, D ;
Hammer, J ;
Nagy, ZA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06) :2635-2644
[10]   Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1:: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes [J].
Jäger, E ;
Chen, YT ;
Drijfhout, JW ;
Karbach, J ;
Ringhoffer, M ;
Jäger, D ;
Arand, M ;
Wada, H ;
Noguchi, Y ;
Stockert, E ;
Old, LJ ;
Knuth, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (02) :265-270